{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T20:42:24Z","timestamp":1777495344592,"version":"3.51.4"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T00:00:00Z","timestamp":1755648000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T00:00:00Z","timestamp":1755648000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"ANID\/FONDECYT","award":["11220149"],"award-info":[{"award-number":["11220149"]}]},{"name":"ANID\/FONDECYT grant","award":["1220353"],"award-info":[{"award-number":["1220353"]}]},{"name":"ANID\/IMII:","award":["ICN09-016\/ICN 2021-045"],"award-info":[{"award-number":["ICN09-016\/ICN 2021-045"]}]},{"name":"N\u00facleo NIBApi","award":["VIDCA Grant #INID210009"],"award-info":[{"award-number":["VIDCA Grant #INID210009"]}]},{"DOI":"10.13039\/501100016014","name":"Fondo de Innovaci\u00f3n para la Competitividad","doi-asserted-by":"publisher","award":["FIC21-19"],"award-info":[{"award-number":["FIC21-19"]}],"id":[{"id":"10.13039\/501100016014","id-type":"DOI","asserted-by":"publisher"}]},{"name":"INID\/ANID","award":["210009"],"award-info":[{"award-number":["210009"]}]},{"name":"ANID\/FONDECYT","award":["1250780"],"award-info":[{"award-number":["1250780"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Biol Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Gallbladder cancer (GBC) is a highly lethal malignancy, often diagnosed at advanced stages when curative options are limited. Its rapid progression and high metastatic potential result in a 5-year survival rate below 5%. Recent evidence highlights the role of Endothelin-1 (ET1), a bioactive peptide, in promoting tumor aggressiveness through activation of its receptors (ETRs). However, therapeutic strategies have mainly focused on receptor inhibition, neglecting the modulation of ET1 availability. Therefore, this study aimed to evaluate the therapeutic potential of modulating ET1 levels through the application of recombinant Neprilysin (rNEP) to degrade ET1 or inhibition of Endothelin Converting Enzyme-1 (ECE1) to reduce its production in GBC cells.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>The effects of rNEP and the ECE1 inhibitor SM19712 were evaluated in GBC cell lines by assessing ET1 levels, nuclear \u03b2-catenin localization, transcript levels of target genes, and changes in proliferation, migration, invasion, and stemness-associated markers in vitro.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Both rNEP and SM19712 significantly reduced extracellular ET1 levels, nuclear \u03b2-catenin localization, and expression of genes such as CCND1, VEGFA, and BIRC5. Treatment also decreased the expression of EMT and stemness markers CD44 and Vimentin. Functionally, rNEP reduced cell migration, invasion, and colony formation, while SM19712 affected migration and colony formation. Isoform analysis revealed predominant expression of ECE1c, suggesting potential ET1-independent roles in invasion.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Modulating ET1 bioavailability through enzymatic degradation or inhibition of its synthesis reduces aggressiveness in GBC cells. These findings support the use of rNEP and ECE1 inhibition as promising strategies for GBC treatment, although further in vivo validation is required.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s40659-025-00637-y","type":"journal-article","created":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T02:46:57Z","timestamp":1755658017000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Decreased Endothelin-1 bioavailability impairs aggressiveness of gallbladder cancer cells"],"prefix":"10.1186","volume":"58","author":[{"given":"Jetzabel","family":"Vidal-Vidal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Brown-Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nelson","family":"Quilaqueo-Millaqueo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaspar","family":"Pe\u00f1a-M\u00fcnzenmayer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Spichiger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Quezada-Monr\u00e1s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Flavio","family":"Salazar-Onfray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1678-2708","authenticated-orcid":false,"given":"Julio C.","family":"Tapia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1857-8698","authenticated-orcid":false,"given":"Ignacio","family":"Niechi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,20]]},"reference":[{"issue":"1","key":"637_CR1","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41572-022-00398-y","volume":"8","author":"JC Roa","year":"2022","unstructured":"Roa JC, Garc\u00eda P, Kapoor VK, Maithel SK, Javle M, Koshiol J. Gallbladder cancer. Nat Rev Dis Primers. 2022;8(1):69.","journal-title":"Nat Rev Dis Primers"},{"issue":"16","key":"637_CR2","doi-asserted-by":"publisher","first-page":"4033","DOI":"10.3390\/cancers15164033","volume":"15","author":"L Zollner","year":"2023","unstructured":"Zollner L, Boekstegers F, Barahona Ponce C, Scherer D, Marcelain K, G\u00e1rate-Calder\u00f3n V, Waldenberger M, Morales E, Rojas A, Munoz C, et al. Gallbladder cancer risk and Indigenous South American Mapuche ancestry: instrumental variable analysis using Ancestry-Informative markers. Cancers. 2023;15(16):4033.","journal-title":"Cancers"},{"issue":"13","key":"637_CR3","doi-asserted-by":"publisher","first-page":"3440","DOI":"10.3390\/cancers15133440","volume":"15","author":"A Tittarelli","year":"2023","unstructured":"Tittarelli A, Barr\u00eda O, Sanders E, Bergqvist A, Brange DU, Vidal M, Gleisner MA, Vergara JR, Niechi I, Flores I, Pereda C, Carrasco C, Quezada-Monr\u00e1s C, Salazar-Onfray F. Co-Expression of immunohistochemical markers MRP2, CXCR4, and PD-L1 in gallbladder tumors is associated with prolonged patient survival. Cancers (Basel). 2023;15(13):3440.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"637_CR4","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1186\/s12935-023-03145-9","volume":"23","author":"F Rodas","year":"2023","unstructured":"Rodas F, Vidal-Vidal JA, Herrera D, Brown-Brown DA, Vera D, Veliz J, P\u00fcschel P, Erices JI, S\u00e1nchez Hinojosa V, Tapia JC, Silva-Pavez E, Quezada-Monr\u00e1s C, Mendoza-Soto P, Salazar-Onfray F, Carrasco C, Niechi I. Targeting the Endothelin-1 pathway to reduce invasion and chemoresistance in gallbladder cancer cells. Cancer Cell Int. 2023;23(1):318.","journal-title":"Cancer Cell Int"},{"key":"637_CR5","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.canlet.2019.03.033","volume":"452","author":"JC Tapia","year":"2019","unstructured":"Tapia JC, Niechi I. Endothelin-converting enzyme-1 in cancer aggressiveness. Cancer Lett. 2019;452:152\u20137.","journal-title":"Cancer Lett"},{"key":"637_CR6","doi-asserted-by":"publisher","first-page":"173727","DOI":"10.1016\/j.ejphar.2020.173727","volume":"891","author":"R Sankhe","year":"2021","unstructured":"Sankhe R, Pai SRK, Kishore A. Tumour suppression through modulation of Neprilysin signaling: A comprehensive review. Eur J Pharmacol. 2021;891:173727.","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"637_CR7","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s13046-016-0401-4","volume":"35","author":"L Rosan\u00f2","year":"2016","unstructured":"Rosan\u00f2 L, Bagnato A. \u03b2-arrestin1 at the cross-road of endothelin-1 signaling in cancer. J Exp Clin Cancer Res. 2016;35(1):121.","journal-title":"J Exp Clin Cancer Res"},{"issue":"13\u201314","key":"637_CR8","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1016\/j.lfs.2008.01.008","volume":"82","author":"WM Zhang","year":"2008","unstructured":"Zhang WM, Zhou J, Ye QJ. Endothelin-1 enhances proliferation of lung cancer cells by increasing intracellular free Ca2+. Life Sci. 2008;82(13\u201314):764\u201371.","journal-title":"Life Sci"},{"issue":"42","key":"637_CR9","doi-asserted-by":"publisher","first-page":"5066","DOI":"10.1038\/onc.2012.527","volume":"17","author":"L Rosan\u00f2","year":"2013","unstructured":"Rosan\u00f2 L, Cianfrocca R, Tocci P, Spinella F, Di Castro V, Spadaro F, et al. \u03b2-arrestin-1 is a nuclear transcriptional regulator of endothelin-1-induced \u03b2-catenin signaling. Oncogene. 2013;17(42):5066\u201377.","journal-title":"Oncogene"},{"issue":"2","key":"637_CR10","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.lfs.2014.01.078","volume":"118","author":"R Cianfrocca","year":"2014","unstructured":"Cianfrocca R, Tocci P, Semprucci E, Spinella F, Di Castro V, Bagnato A, et al. \u03b2-Arrestin 1 is required for endothelin-1-induced NF-\u03baB activation in ovarian cancer cells. Life Sci. 2014;118(2):179\u201384.","journal-title":"Life Sci"},{"issue":"8","key":"637_CR11","doi-asserted-by":"publisher","first-page":"2806","DOI":"10.1073\/pnas.0807158106","volume":"106","author":"L Rosan\u00f2","year":"2009","unstructured":"Rosan\u00f2 L, Cianfrocca R, Masi S, Spinella F, Di Castro V, Biroccio A, et al. Beta-arrestin links endothelin A receptor to beta-catenin signaling to induce ovarian cancer cell invasion and metastasis. Proc Natl Acad Sci U S A. 2009;106(8):2806\u201311.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"637_CR12","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1038\/nm0995-944","volume":"1","author":"JB Nelson","year":"1995","unstructured":"Nelson JB, Hedican SP, George DJ, Reddi AH, Piantadosi S, Eisenberger MA, et al. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med. 1995;1(9):944\u20139.","journal-title":"Nat Med"},{"issue":"Suppl 1","key":"637_CR13","first-page":"E85","volume":"53","author":"S Nie","year":"2014","unstructured":"Nie S, Zhou J, Bai F, Jiang B, Chen J, Zhou J. Role of endothelin A receptor in colon cancer metastasis: in vitro and in vivo evidence. Mol Carcinog. 2014;53(Suppl 1):E85\u201391.","journal-title":"Mol Carcinog"},{"issue":"2","key":"637_CR14","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.neo.2019.11.001","volume":"22","author":"S Gupta","year":"2020","unstructured":"Gupta S, Prajapati A, Gulati M, Gautam SK, Kumar S, Dalal V, et al. Irreversible and sustained upregulation of endothelin axis during oncogene-associated pancreatic inflammation and cancer. Neoplasia. 2020;22(2):98\u2013110.","journal-title":"Neoplasia"},{"issue":"1","key":"637_CR15","first-page":"2","volume":"8","author":"K Papadopoulou","year":"2018","unstructured":"Papadopoulou K, Murray S, Manousou K, Tikas I, Dervenis C, Sgouros J, et al. Genotyping and mRNA profiling reveal actionable molecular targets in biliary tract cancers. Am J Cancer Res. 2018;8(1):2\u201315.","journal-title":"Am J Cancer Res"},{"issue":"1","key":"637_CR16","first-page":"25","volume":"23","author":"C Ge","year":"2021","unstructured":"Ge C, Zhu X, Niu X, Zhang B, Chen L. A transcriptome profile in gallbladder cancer based on annotation analysis of microarray studies. Mol Med Rep. 2021;23(1):25.","journal-title":"Mol Med Rep"},{"issue":"1","key":"637_CR17","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s13046-022-02317-1","volume":"41","author":"R Sestito","year":"2022","unstructured":"Sestito R, Tocci P, Roman C, Di Castro V, Bagnato A. Functional interaction between endothelin-1 and ZEB1\/YAP signaling regulates cellular plasticity and metastasis in high-grade serous ovarian cancer. J Exp Clin Cancer Res. 2022;41(1):157.","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"637_CR18","doi-asserted-by":"publisher","first-page":"15931","DOI":"10.1038\/s41598-020-72960-1","volume":"10","author":"L Kappes","year":"2020","unstructured":"Kappes L, Amer RL, Sommerlatte S, Bashir G, Plattfaut C, Gieseler F, et al. Ambrisentan, an endothelin receptor type A-selective antagonist, inhibits cancer cell migration, invasion, and metastasis. Sci Rep. 2020;10(1):15931.","journal-title":"Sci Rep"},{"issue":"6","key":"637_CR19","doi-asserted-by":"publisher","first-page":"R469","DOI":"10.1152\/ajpregu.00532.2015","volume":"310","author":"L Rosan\u00f2","year":"2016","unstructured":"Rosan\u00f2 L, Bagnato A. Endothelin therapeutics in cancer: where are we? Am J Physiol Regul Integr Comp Physiol. 2016;310(6):R469\u201375.","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"issue":"1","key":"637_CR20","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.bbapap.2004.11.001","volume":"1751","author":"M Sumitomo","year":"2005","unstructured":"Sumitomo M, Shen R, Nanus DM. Involvement of neutral endopeptidase in neoplastic progression. Biochim Biophys Acta. 2005;1751(1):52\u20139.","journal-title":"Biochim Biophys Acta"},{"issue":"40","key":"637_CR21","doi-asserted-by":"publisher","first-page":"42749","DOI":"10.18632\/oncotarget.5722","volume":"6","author":"I Niechi","year":"2015","unstructured":"Niechi I, Silva E, Cabello P, Huerta H, Carrasco V, Villar P, Cataldo LR, Marcelain K, Armisen R, Varas-Godoy M, Fernandez C, Tapia JC. Colon cancer cell invasion is promoted by protein kinase CK2 through increase of endothelin-converting enzyme-1c protein stability. Oncotarget. 2015;6(40):42749\u201360.","journal-title":"Oncotarget"},{"issue":"1","key":"637_CR22","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1254\/jjp.84.7","volume":"84","author":"K Umekawa","year":"2000","unstructured":"Umekawa K, Hasegawa H, Tsutsumi Y, Sato K, Matsumura Y, Ohashi N. Pharmacological characterization of a novel sulfonylureid-pyrazole derivative, SM-19712, a potent nonpeptidic inhibitor of endothelin converting enzyme. Jpn J Pharmacol. 2000;84(1):7\u201315.","journal-title":"Jpn J Pharmacol"},{"issue":"2","key":"637_CR23","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1002\/1878-0261.12609","volume":"14","author":"P P\u00e9rez-Moreno","year":"2020","unstructured":"P\u00e9rez-Moreno P, Indo S, Niechi I, Huerta H, Cabello P, Jara L, et al. Endothelin-converting enzyme-1c promotes stem cell traits and aggressiveness in colorectal cancer cells. Mol Oncol. 2020;14(2):347\u201362.","journal-title":"Mol Oncol"},{"issue":"3","key":"637_CR24","doi-asserted-by":"publisher","first-page":"506","DOI":"10.3390\/cells12030506","volume":"12","author":"I Niechi","year":"2023","unstructured":"Niechi I, Erices JI, Carrillo-Beltr\u00e1n D, Uribe-Ojeda A, Torres \u00c1, Rocha JD, Uribe D, Toro MA, Villalobos-Nova K, Gaete-Ram\u00edrez B, Mingo G, Owen GI, Varas-Godoy M, Jara L, Aguayo F, Burzio VA, Quezada-Monr\u00e1s C, Tapia JC. Cancer stem cell and aggressiveness traits are promoted by stable Endothelin-Converting Enzyme-1c in glioblastoma cells. Cells. 2023;12(3):506.","journal-title":"Cells"},{"issue":"1","key":"637_CR25","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s40659-024-00551-9","volume":"57","author":"C Almarza","year":"2024","unstructured":"Almarza C, Villalobos-Nova K, Toro MA, Gonz\u00e1lez M, Niechi I, Brown-Brown DA, L\u00f3pez-Mu\u00f1oz RA, Silva-Pavez E, Gaete-Ram\u00edrez B, Varas-Godoy M, Burzio VA, Jara L, Aguayo F, Tapia JC. Cisplatin-resistance and aggressiveness are enhanced by a highly stable endothelin-converting enzyme-1c in lung cancer cells. Biol Res. 2024;57(1):74. https:\/\/doi.org\/10.1186\/s40659-024-00551-9","journal-title":"Biol Res"},{"issue":"1","key":"637_CR26","first-page":"95","volume":"1","author":"S Homma","year":"1988","unstructured":"Homma S, Hasumura S, Nagamori S, Kameda H. Establishment and characterization of a human gallbladder carcinoma cell line NOZ. Hum Cell. 1988;1(1):95\u20137.","journal-title":"Hum Cell"},{"issue":"12","key":"637_CR27","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1007\/s00262-018-2157-5","volume":"67","author":"D Rojas-Sep\u00falveda","year":"2018","unstructured":"Rojas-Sep\u00falveda D, Tittarelli A, Gleisner MA, \u00c1valos I, Pereda C, Gallegos I, et al. Tumor lysate-based vaccines: on the road to immunotherapy for gallbladder cancer. Cancer Immunol Immunother. 2018;67(12):1897\u2013910.","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"637_CR28","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S1535-6108(03)00331-3","volume":"5","author":"M Sumitomo","year":"2004","unstructured":"Sumitomo M, Iwase A, Zheng R, Navarro D, Kaminetzky D, Shen R, Georgescu MM, Nanus DM. Synergy in tumor suppression by direct interaction of neutral endopeptidase with PTEN. Cancer Cell. 2004;5(1):67\u201378.","journal-title":"Cancer Cell"},{"key":"637_CR29","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.3389\/fonc.2020.01004","volume":"10","author":"P P\u00e9rez-Moreno","year":"2020","unstructured":"P\u00e9rez-Moreno P, Quezada-Meza C, Chavez-Almarza C, Niechi I, Silva-Pavez E, Trigo-Hidalgo C, Aguayo F, Jara L, C\u00e1ceres-Verschae A, Varas-Godoy M, D\u00edaz VM, de Garc\u00eda A, Burzio VA, Tapia JC. Phosphorylation of Endothelin-Converting Enzyme-1c at Serines 18 and 20 by CK2 promotes aggressiveness traits in colorectal cancer cells. Front Oncol. 2020;10:1004.","journal-title":"Front Oncol"},{"issue":"10","key":"637_CR30","doi-asserted-by":"publisher","first-page":"e13134","DOI":"10.1371\/journal.pone.0013134","volume":"5","author":"M Siepmann","year":"2010","unstructured":"Siepmann M, Kumar S, Mayer G, Walter J. Casein kinase 2 dependent phosphorylation of Neprilysin regulates receptor tyrosine kinase signaling to Akt. PLoS ONE. 2010;5(10):e13134.","journal-title":"PLoS ONE"},{"key":"637_CR31","doi-asserted-by":"publisher","first-page":"545","DOI":"10.3389\/fonc.2020.00545","volume":"10","author":"M Wencong","year":"2020","unstructured":"Wencong M, Jinghan W, Yong Y, Jianyang A, Bin L, Qingbao C, Chen L, Xiaoqing J. FOXK1 promotes proliferation and metastasis of gallbladder cancer by activating akt\/mtor signaling pathway. Front Oncol. 2020;10:545.","journal-title":"Front Oncol"},{"issue":"2","key":"637_CR32","doi-asserted-by":"publisher","first-page":"153","DOI":"10.3390\/diagnostics11020153","volume":"11","author":"C Carrasco","year":"2021","unstructured":"Carrasco C, Tittarelli A, Paillaleve N, Pozo MD, Rojas-Sep\u00falveda D, Barr\u00eda O, Flux\u00e1 P, Hott M, Martin C, Quezada C, Salazar-Onfray F. The evaluation of 17 Gastrointestinal tumor markers reveals prognosis value for MUC6, CK17, and CD10 in Gallbladder-Cancer patients. Diagnostics (Basel). 2021;11(2):153.","journal-title":"Diagnostics (Basel)"},{"issue":"3","key":"637_CR33","doi-asserted-by":"publisher","first-page":"771","DOI":"10.3892\/ijo.2017.4063","volume":"51","author":"T Miwa","year":"2017","unstructured":"Miwa T, Nagata T, Kojima H, Sekine S, Okumura T. Isoform switch of CD44 induces different chemotactic and tumorigenic ability in gallbladder cancer. Int J Oncol. 2017;51(3):771\u201380.","journal-title":"Int J Oncol"},{"issue":"1","key":"637_CR34","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13046-020-01812-7","volume":"6","author":"Y Shi","year":"2021","unstructured":"Shi Y, Sun L, Zhang R, Hu Y, Wu Y, Dong X, Dong D, Chen C, Geng Z, Li E, Fan Y. Thrombospondin 4\/integrin \u03b12\/HSF1 axis promotes proliferation and cancer stem-like traits of gallbladder cancer by enhancing reciprocal crosstalk between cancer-associated fibroblasts and tumor cells. J Exp Clin Cancer Res. 2021;6(1):14.","journal-title":"J Exp Clin Cancer Res"},{"issue":"18","key":"637_CR35","doi-asserted-by":"publisher","first-page":"3447","DOI":"10.1111\/bph.14593","volume":"176","author":"NN Nalivaeva","year":"2019","unstructured":"Nalivaeva NN, Turner AJ. Targeting amyloid clearance in alzheimer\u2019s disease as a therapeutic strategy. Br J Pharmacol. 2019;176(18):3447\u201363.","journal-title":"Br J Pharmacol"},{"key":"637_CR36","doi-asserted-by":"publisher","first-page":"649646","DOI":"10.3389\/fnagi.2021.649646","volume":"13","author":"C Humpel","year":"2021","unstructured":"Humpel C. Intranasal delivery of Collagen-Loaded Neprilysin clears Beta-Amyloid plaques in a Transgenic alzheimer mouse model. Front Aging Neurosci. 2021;13:649646.","journal-title":"Front Aging Neurosci"},{"key":"637_CR37","doi-asserted-by":"publisher","first-page":"111363","DOI":"10.1016\/j.mad.2020.111363","volume":"192","author":"NN Nalivaeva","year":"2020","unstructured":"Nalivaeva NN, Zhuravin IA, Turner AJ. Neprilysin expression and functions in development, ageing and disease. Mech Ageing Dev. 2020;192:111363.","journal-title":"Mech Ageing Dev"},{"issue":"7","key":"637_CR38","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1038\/sj.bjc.6604631","volume":"99","author":"LA Lambert","year":"2008","unstructured":"Lambert LA, Whyteside AR, Turner AJ, Usmani BA. Isoforms of endothelin-converting enzyme-1 (ECE1) have opposing effects on prostate cancer cell invasion. Br J Cancer. 2008;99(7):1114\u201320. https:\/\/doi.org\/10.1038\/sj.bjc.6604631. Epub 2008 Sep 9. PMID: 18781169; PMCID: PMC2567069.","journal-title":"Br J Cancer"},{"issue":"8","key":"637_CR39","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1139\/Y10-054","volume":"88","author":"AR Whyteside","year":"2010","unstructured":"Whyteside AR, Hinsley EE, Lambert LA, McDermott PJ, Turner AJ. ECE1 influences prostate cancer cell invasion via ET-1-mediated FAK phosphorylation and ET-1-independent mechanisms. Can J Physiol Pharmacol. 2010;88(8):850\u20134.","journal-title":"Can J Physiol Pharmacol"},{"key":"637_CR40","first-page":"e3612","volume":"28","author":"L Chen","year":"2023","unstructured":"Chen L, Lu Y, Zhao M, Xu J, Wang Y, Xu Q, Cao Y, Liu H. A non-canonical role of endothelin converting enzyme 1 (ECE1) in promoting lung cancer development via directly targeting protein kinase B (AKT). J Gene Med. 2023;28:e3612.","journal-title":"J Gene Med"},{"issue":"6","key":"637_CR41","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1139\/Y08-023","volume":"86","author":"W Goettsch","year":"2008","unstructured":"Goettsch W, Schubert A, Morawietz H. Expression of human endothelin-converting enzyme isoforms: role of angiotensin II. Can J Physiol Pharmacol. 2008;86(6):299\u2013309.","journal-title":"Can J Physiol Pharmacol"}],"container-title":["Biological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40659-025-00637-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40659-025-00637-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40659-025-00637-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T17:24:18Z","timestamp":1757438658000},"score":1,"resource":{"primary":{"URL":"https:\/\/biolres.biomedcentral.com\/articles\/10.1186\/s40659-025-00637-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,20]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["637"],"URL":"https:\/\/doi.org\/10.1186\/s40659-025-00637-y","relation":{},"ISSN":["0717-6287"],"issn-type":[{"value":"0717-6287","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,20]]},"assertion":[{"value":"18 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no conflicts of interest to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"57"}}